IFP Advisors’s Foghorn Therapeutics FHTX Stock Holding History

IFP Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$8	–	4626
2025 Q1	$7	Hold	2	–	–	﹤0.01%	4251
2024 Q4	$9	Buy	+2	New	+$15	﹤0.01%	4534

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

IFP Advisors's FHTX Position: Q2 2025 in Review

IFP Advisors sold out of Foghorn Therapeutics (FHTX) in Q2 2025, closing a stake of 2 shares — an estimated $8 sold.

IFP Advisors first reported a position in FHTX in Q4 2024 and held it in 2 quarters. The position peaked at $9 in Q4 2024. 81 funds tracked by Wall St. Rank hold FHTX as of Q2 2025.

IFP Advisors reported no remaining Foghorn Therapeutics position as of Q2 2025 after selling out during the quarter.
IFP Advisors sold 2 Foghorn Therapeutics shares in Q2 2025, an estimated $8.
IFP Advisors first reported a position in Foghorn Therapeutics in Q4 2024 and held it in 2 quarters.
IFP Advisors's Foghorn Therapeutics position peaked at $9 in Q4 2024.
81 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.